Bupropion

Bupropion has been studied in 30 papers since 2016: 4 trials and 13 observational studies in people, 11 reviews; 22 in the past year. It is an approved medicine. The newest paper, Nov 3, 2026: “From prescription to prognosis: longitudinal associations between different antidepressant classes on medical comorbidity in those with bipolar disorder”.

InterventionApproved 1985

30 papers study it31 more mention it11 findingsUpdated

PubChemChEBIMeSH

7 new papers in 30 daysSee all 61 papers on bupropion

At a glance

Independent labs found the same change in people. 9 independent labs in 9 countries; 208 trials, none about aging, 89 with no results posted.

“Bupropion was also associated with lower risk of MACE (HR 0.75; 95% CI 0.73-0.77)”
Association of Major Adverse Cardiovascular Events with Varenicline versus BupropionAHA Scientific Sessions 2026 abstract2026doi:10.1161/circ.154.suppl_1.11941

None of its findings points the other way.

Humans: replicated by independent labs. Cells, worms or flies and mice: nothing yet.
  • 9 independent labs in 9 countries
  • 208 trials, none about aging, 89 with no results posted
  • Funders: Alzheimer's Association and others
  • 27 of 208 trials sponsored by its developers
  • Human trial4
  • Humans13
  • In silico1

Studies in people

1 study gave bupropion to people and measured what changed.

What changedDesignPeopleSource

no change: Has no effect on smoking abstinencep = 0.277

Treated cohort12 weeks169 peopleBoth51.5±9 yearsMidlife adults; Patient cohortsESC Congress 2026 abstract, Oct 26, 2026

What did studies of bupropion find?

5

Studies of bupropion measured 5 outcomes, among them smoking cessation, smoking abstinence and memory.

Smoking cessation

upin humans2

2 studies
  1. Bupropion improves smoking cessation in StUD.

    “Bupropion demonstrated efficacy in StUD but limited evidence in other disorders.”

    Reviewin StUD

    Pharmacological Smoking Cessation Interventions in People with Cannabis, Opioid, or Stimulant Use Disorders: A Systematic Review

    Research SquarePreprint

  2. Bupropion increases smoking cessation in humans.

    “Nicotine replacement, bupropion and varenicline were effective for smoking cessation, an outcome that can significantly lower cardiometabolic risk.”

    Review

    Pharmacological interventions to manage cardiometabolic outcomes in adults with severe mental illness: umbrella review

    The British journal of psychiatry : the journal of mental science

Smoking abstinence

no changein humans1

1 study
  1. Bupropion was not clearly linked with smoking abstinence in humans (p = 0.277).

    “the relevant association in bupropion therapy was not significant (p = 0.277)”

    HumansCompared with nicotine replacement therapy; adjusted for cardiovascular disease history, pack-years, and nicotine dependence12 weeksn = 169

    Breaking the habit: comparative effectiveness of smoking cessation therapies in a cardiovascular hospital based clinical setting

    ESC Congress 2026 abstract

Memory

upin humans1

1 study
  1. Bupropion is linked with better memory in humans.

    “Estradiol, naproxen, bupropion, and the combined use of triamterene and hydrochlorothiazide were found to enhance performance on 2 memory cognitive tests, immediate recall and delayed recall”

    Humans

    National database analysis of prescription medication uses and cognitive function in older adults: An observational study

    Medicine

Long-term smoking abstinence

upin humans1

1 study
  1. Bupropion increases long-term smoking abstinence in humans (severe mental illness; compared with placebo or minimal care) (5 more per 100 achieving long-term smoking abstinence, 95% CI 1 to 10).

    “bupropion (5 more per 100, 1 to 10; moderate certainty evidence) increased long term abstinence.”

    Reviewsevere mental illness; compared with placebo or minimal care

    Smoking cessation for people with severe mental illness: systematic review and network meta-analysis

    BMJ medicine

Alzheimer's disease progression

downin humans1HR 0.57

1 study
  1. Bupropion is linked with lower alzheimer's disease progression in humans (mild cognitive impairment) (HR 0.57 [0.49, 0.66]).

    “bupropion (vs. escitalopram: difference: ‐0.06 [‐0.08, ‐0.05], P=0.002; hazard ratio [HR]: 0.57 [0.49, 0.66], P<0.001)”

    Humansmild cognitive impairment

    Critical real‐world patient data observation of repurposable drugs from Alzheimer's disease drug development pipeline using Target Trial Emulation

    AAIC 2025 abstract

What is bupropion linked with?

4

Studies link bupropion with 4 measures, among them major adverse cardiovascular events, smoking cessation and mortality.

Major adverse cardiovascular events

downin humans2HR 0.75

2 studies
  1. Bupropion is associated with major adverse cardiovascular events in humans (Nicotine or tobacco dependence; compared with no bupropion use) (HR 0.75; 95% CI 0.73-0.77).

    “Bupropion was also associated with lower risk of MACE (HR 0.75; 95% CI 0.73-0.77)”

    HumansNicotine or tobacco dependence; compared with no bupropion use3 yearsn = 152,436

    Association of Major Adverse Cardiovascular Events with Varenicline versus Bupropion

    AHA Scientific Sessions 2026 abstract

  2. Bupropion is associated with major adverse cardiovascular events in humans.

    “Both varenicline and bupropion individually showed lower mortality and MACE.”

    HumansAfter acute coronary syndrome; added to nicotine replacement therapy versus nicotine replacement therapy alone

    Addition of Bupropion or Varenicline to Nicotine Replacement Therapy After Acute Coronary Syndrome: A Propensity-Matched Real-World Analysis

    AHA Scientific Sessions 2026 abstract

Smoking cessation

upin humans1HR 2.25

1 study
  1. Bupropion is associated with smoking cessation in humans (HR 2.25; 95% CI 2.06-2.45).

    “Both therapies increased smoking cessation (varenicline HR 2.32; 95% CI 2.12-2.53; bupropion HR 2.25; 95% CI 2.06-2.45).”

    HumansNicotine or tobacco dependence; compared with no bupropion use; cessation identified by ICD-10 code3 yearsn = 152,436

    Association of Major Adverse Cardiovascular Events with Varenicline versus Bupropion

    AHA Scientific Sessions 2026 abstract

Mortality

downin humans1

1 study
  1. Bupropion is associated with mortality in humans.

    “Both varenicline and bupropion individually showed lower mortality and MACE.”

    HumansAfter acute coronary syndrome; added to nicotine replacement therapy versus nicotine replacement therapy alone

    Addition of Bupropion or Varenicline to Nicotine Replacement Therapy After Acute Coronary Syndrome: A Propensity-Matched Real-World Analysis

    AHA Scientific Sessions 2026 abstract

Alzheimer's disease

downin humans1HR 0.57

1 study
  1. Bupropion is linked with a lower risk of Alzheimer's disease in humans (active comparator vs escitalopram, MCI cohort) (HR 0.57, 95% CI 0.49–0.66).

    “Active comparator analyses indicated that bupropion (vs escitalopram; HR 0.57, 95% confidence interval [CI] [0.49, 0.66]”

    Humansactive comparator vs escitalopram, MCI cohort

    Critical evaluation of real-world evidence of repurposable medicines in the Alzheimer's disease drug development pipeline using a target trial emulation

    Alzheimer's & dementia (New York, N. Y.)

More on Alzheimer's disease

Has bupropion been tested in people?

0 of 208 about aging

Yes: 4 trials and 13 observational studies in people have been published, and 207 trials are registered.

Approved

Repurposing

40 of 82

In trials

  • Cigarette smoking

    Phase 4Results posted5 trials

  • Tobacco use cessation

    Phase 4Completed4 trials

  • Physiological sexual dysfunction

    Phase 4Completed3 trials

  • Cigarette smoking-related carcinoma

    Phase 4Recruiting1 trial

  • Roux-en-y gastric bypass

    Phase 4Completed1 trial

  • Psychological sexual dysfunction

    Phase 3Completed4 trials

All 14

Stopped

  • NCT02238977TerminatedMajor depressive disorder

    Study stopped due to difficulty recruiting

  • NCT03993457TerminatedMajor depressive disorder

    terminated during COVID due to inability to see participants in person.

  • NCT00181896TerminatedDepression

    Study was terminated due to lack of recruitment

  • NCT00119210TerminatedTobacco use disorder

    We were unable to recruit sufficient numbers of patients and decided that the study protocol was not feasible to implement

  • NCT04531176TerminatedObesity

    After an unplanned yet IRB approved interim analysis, it was found that there was not a significant difference between the 3 arms of the study. The study was closed due to futility. All Patients are off study and this study will not resume.

  • NCT01219673TerminatedCarcinoma

    Low accrual.

All 7

Who is developing bupropion?

3 companies: Bausch Health Americas, Rose Research Center and Boehringer Ingelheim.

Companies
  • Bausch Health AmericasPhase 4Major depressive disorder
  • Rose Research CenterPhase 3smoking cessation
  • Boehringer IngelheimPhase 1overweight, obesity

Trial sponsors

Latest

Dec 2025: 4Jan 2026: 4Feb 2026: 6Mar 2026: 7Apr 2026: 0May 2026: 3Jun 2026: 2Jul 2026: 1Aug 2026: 0Sep 2026: 3Oct 2026: 4Nov 2026: 438 papers in 12 months

See all 61 papers on bupropion